Xiuning Le, Associate Professor, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared a post on LinkedIn:
“It takes coordinated effort, many talents, and close collaboration to push the boundaries in precision oncology .
Dr. Ximeng Liu has been selected for support from the Lung Cancer Research Foundation (LCRF) Dhruba (Dhru) Deb, Ph.D. for her project: ‘Deciphering response and resistance mechanisms to firmonertinib in NSCLC patients with EGFR PACC mutations.’
Our journey advancing the science of EGFR PACC NSCLC has been remarkable:
- 2021: Defined EGFR PACC mutations as a distinct structure–function subgroup in lung cancer.
- 2023–2024: Partnered with ArriVent Biopharma on the first prospective trial dedicated to EGFR PACC patients — 68% response rate and 16.0 months PFS with firmonertinib.
- 2025: Launched the first global randomized phase III trial in EGFR PACC–mutant NSCLC (ALPACCA/FURMO-006; NCT07185997)
- 2026–2027: With LCRF support, Dr. Liu will lead efforts to decipher resistance mechanisms and shape next-generation therapeutic strategies.
More exciting developments are on the horizon. ”
More posts featuring Xiuning Le.